Resource
Monoclonal gammopathy of undetermined significance (MGUS) is a non-cancerous condition associated with the possible subsequent development of myeloma. Smoldering multiple myeloma (SMM) is an asymptomatic precursor to active disease; the FDA granted its first-ever approval of a treatment for SMM in…
Videos
Why Don’t We Treat MGUS? What MGUS Means for Multiple Myeloma Risk If MGUS can become multiple myeloma, why don't doctors treat it? IMF Medical Advisor Dr. Joseph Mikhael explains why MGUS is typically not treated and why routine monitoring is important.Learn what MGUS means, why most people…
Blog post
One Patient Hopes His Voice Will Raise Overall Myeloma AwarenessThe International Myeloma Foundation continues to share this collection of patient and care partner stories from those who have completed the Legislative Advocacy Master Class (LAMC). The IMF hopes that these unique and compelling…
Blog post
Author insights from iStopMM Project team members on the newest published results from the iStopMM study. This year, iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma) will be celebrating its 10th year since its start. The study has had a big impact on the field of myeloma…
Blog post
MGUS and Smoldering Myeloma at ASH 2025: What’s NewBy Jessie Daw, PhDThe 2025 American Society of Hematology (ASH) meeting moved fast, and attending virtually didn’t slow the pace. As a virtual member of the International Myeloma Foundation’s (IMF) Myeloma Voices team, I was busy,…
Blog post
One Mom’s Story of Living with Myeloma While Raising Two Children In 2013, Sue Massey received a diagnosis of monoclonal gammopathy of undetermined significance (MGUS). She was married at the time and had a four-year-old daughter. Because she had a young child…
Blog post
A summary of some notable key multiple myeloma research from July-August 2026 Scope and Methodology This week’s blog summarizes key multiple myeloma research published in several peer-reviewed publications and medical journals from July-August 2026. Content…
Blog post
MGUS & Smoldering Myeloma in 2025: iStopMM Screening and Risk Updates The iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma) study in…
Resource
Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21,463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom’s macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is…
Blog post
There are several wonderful pieces of myeloma-related news this week that deserve to be shared. From Iceland to China, here are the highlights. Iceland’s iStopMM Project Published in ‘Nature Medicine’There is great news for the IMF-supported iStopMM (Iceland Screens…
Blog post
A bit of good news this week for the myeloma community: a recent breakthrough in myeloma research was made by a group of Spanish researchers.
Headed by Dr. Bruno Paiva (University of Navarra—Pamplona, Spain), a group of…
Blog post
iStopMM Report from Iceland
The IMF team just returned from the exciting iStopMM kickoff meeting held on September 26-27th at the deCode Genetics facility at the University of…
Blog post
In 2023, we learned about Artificial Intelligence (AI) technology, including the chatbot that was based on a large language model (LLM) called Chat GPT, where we can ask questions and sometimes, get crazy answers.
Despite concerns about hallucinating computers and…
Blog post
An informative conversation between IMF Chief Medical Officer Dr. Joseph Mikhael and IMF Scientific Advisory Board Member Dr. Shaji Kumar on what myeloma patients and their families should expect next in terms of early screening and diagnosis, treatments, and care.
On the second…
Blog post
As we near the end of 2023, I think everyone is ready for a break from an exhausting year.
We came through the COVID pandemic and still remain on alert for what the future may bring. We celebrated the FDA approval of exciting new immune therapies while grappling on how to best use them…
Blog post
Insights from the First Results of the iStopMM Screening Study
May 20, 2021
This week, the IMF is pleased to announce the publication of the first results of the…
Blog post
In February 2020, the looming COVID-19 pandemic began to unfold globally.
This prompted the International Myeloma Foundation (IMF) to reformat its in-person Patient and Family Seminar (PFS) which was scheduled to happen in March. We had to adapt to the situation by holding a Zoom meeting instead…
Blog post
For myeloma patients, “cure” is a magical word. It’s like a coveted pot of gold at the end of the rainbow that disappears like a mirage in the desert as you get closer. This is why it’s very important to have a clear understanding of what “cure” really means and how close we are to…
Blog post
October and November 2025: What’s New in Myeloma? At the end of each month, the International Myeloma Foundation (IMF) brings you some of the latest and most relevant news (myeloma research, clinical trials, treatments, drug authorizations, and more) to give a renewed sense of hope, courage,…
Blog post
As the Asian Myeloma Network’s (AMN) 7th Annual Summit wrapped up in Bangkok on Sunday, October 22nd, I realized that what happens in Asia does not just affect or stay in Asia.
As I will summarize, there are wonderful benefits that came from the 3rd Doctor…
News Article
Riding with PurposeEric Blackburn’s commitment to the IMFBy Simona Grace, IMF Senior Director, DevelopmentWhen Eric Blackburn signed up for the International Myeloma Foundation’s Iceland Cycling Expedition, he committed to a cause that had become deeply personal.A Gulf War veteran…
Videos
Your Multiple Myeloma Questions Answered: Neuropathy, GLP-1s, Treatment Decisions & More What are patients asking about multiple myeloma, CAR T therapy, bispecific antibodies, treatment side effects, and more? In this Q&A, IMF Nurse Leadership Board…
Blog post
On Tuesday, June 17, the International Myeloma Foundation (IMF) conducted its annual webinar on the 2025 IMWG Conference Series: Making Sense of Treatment.
The webinar was hosted by IMF Chief Medical Officer Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO (TGen at the City of…
Blog post
This week there are several interesting items in the news that help us understand how and why monoclonal gammopathy of undetermined significance (MGUS) occurs, and when it may or may not turn into active myeloma.
Matthew Drake and the Mayo Clinic bone…
Videos
Early Signs of Multiple Myeloma: Symptoms, MGUS, and When to See a Doctor If you've searched for MGUS, smoldering myeloma, or early symptoms of multiple myeloma, this video explains what you should know. The International Myeloma Foundation’s…
Videos
MGUS, High-Risk Myeloma, Relapse & Dexamethasone Side Effects | Your Questions AnsweredDoes multiple myeloma come back more aggressively each time? What does it mean to have MGUS? How do you know if myeloma is high risk, and what side effects can dexamethasone…
Blog post
At the end of each month, the International Myeloma Foundation (IMF) brings you some of the latest and most relevant news (myeloma research, clinical trials, treatments, drug authorizations, and more) to give a renewed sense of hope, courage, and resilience to the myeloma community. Through these…
Blog post
The International Myeloma Foundation held a Patient and Family Seminar at the Hilton Los Angeles/Universal City from August 16-17, 2024.
The International Myeloma Foundation (IMF) once again, gathered doctors, patients, and families in Los Angeles to share stories and connect with those…
Blog post
For the first time, direct serum measurements of the known human carcinogen 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in Agent Orange have been linked to the likelihood of developing MGUS (monoclonal gammopathy of undetermined significance) and myeloma. In a…
Videos
Can Multiple Myeloma Be Cured? Dr. Joe Answers Your Biggest Myeloma QuestionsWhy might someone need CAR T-cell therapy while already in remission? And why are some people with MGUS or smoldering myeloma told to wait and watch? In this Q&A, Dr. Joseph…
Blog post
Several historic events occurred this week: It has been 22 years since the 9/11 attacks happened in New York City; FDA approval and CDC endorsement/recommendation of the use of updated COVID-19 vaccines against current and active variants; and significant new findings in myeloma research as…
Blog post
During the height of the recent COVID-19 pandemic, some people became tragically very sick whereas, around 20% of individuals had no symptoms whatsoever.
Why did some people rapidly clear the COVID-19 virus from their system?This question has been taken up by a group of researchers at the…
Videos
MGUS Is a Precursor to Multiple Myeloma
Myeloma expert Dr. Brian G.M. Durie discusses monoclonal gammopathy of undetermined significance (MGUS).
The BOTTOM LINE: Monoclonal gammopathy of undetermined…
Blog post
At the end of each month, the International Myeloma Foundation (IMF) brings you some of the latest and most relevant news (myeloma research, clinical trials, treatments, drug authorizations, and more) to give a renewed sense of hope, courage, and resilience to the myeloma community. …
Blog post
At the end of each month, the International Myeloma Foundation (IMF) brings you some of the latest and most relevant news (myeloma research, clinical trials, treatments, drug authorizations, and more) to give a renewed sense of hope, courage, and resilience to the myeloma community. …
Videos
Should We Screen for MGUS?
The Question the International Myeloma Foundation Aims to Answer With the iStopMM Study
Imagine stopping multiple myeloma before it ever begins. That’s the bold mission behind the iStopMM (Iceland Screens, Treats, or Prevents Multiple…
Blog post
A new study shows that New York City firefighters who responded to the Sept. 11, 2001 World Trade Center terrorist attack are twice as likely to develop the myeloma…
Blog post
A summary of some notable key multiple myeloma research from November-December 2025 Scope and MethodologyThis week’s blog summarizes key multiple myeloma research published in several peer-reviewed publications and medical journals from November-…
Videos
When Should MGUS Patients Undergo Bone Marrow Biopsy?
Myeloma expert Dr. Brian G.M. Durie discusses how the IMF’s iStopMM study results presented at the 2022 American Society of Hematology (ASH) meeting may help predict when a bone marrow biopsy is needed. …
Videos
No Link Found Between Autoimmune Disease and MGUS
Dr. Ingigerdur Sverrisdottir presents an abstract on the relationship between monoclonal gammopathy of undetermined significance (MGUS) and autoimmune diseases.
Abstract title:
Autoimmune Diseases Are Not Associated with Monoclonal…
Videos
Can Multiple Myeloma Ever Be Prevented or Even Cured Before It Becomes Active? | An Interview with Dr. Shaji KumarIn this in-depth interview, Dr. Shaji Kumar, hematologist at Mayo Clinic and member of the IMF's Scientific Advisory Board and International Myeloma Working Group (IMWG),…
Videos
SARS-CoV-2 Vaccination's Impact on the Progression of MGUS to MM
Dr. Robert Palmason discusses the results of a study investigating if SARS-CoV-2 vaccination impacts the risk of progression from MGUS to multiple myeloma
Abstract Title:
105 Sars-…
Videos
Multiple Myeloma Q&A: Why Diagnosis Can Take 12+ Months, MGUS, Costs & FDA News
Answering your myeloma questions! Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, tackles the most pressing concerns from patients and care…
Videos
iStopMM Results of Hypercalcemia in Patients with MGUS
Dr. Ástrún Helga Jónsdóttir presents the results of an iStopMM study regarding hypercalcemia in individuals with Monoclonal Gammopathy of Undetermined Significance (MGUS).
Abstract title:…
Videos
What is MGUS? Understanding Monoclonal Gammopathy of Undetermined Significance in Multiple Myeloma
What is MGUS and how does it affect patients? In this video, Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation,…
Videos
Chronic Kidney Disease in MGUS Patients
Dr. Thorir Einarsson Long presents an abstract to compare the prevalence of chronic kidney disease in individuals with and without monoclonal gammopathy of undetermined significance in a large, prospective, screened, population-based…
Videos
Does MGUS Require Bone Marrow Testing?
A new study from Iceland, part of the IMF's iStopMM project, distinguishes between patients who require bone marrow testing and those who can be safely monitored without immediate bone marrow testing.
The…
Videos
MGUS Cases with Multiple Paraproteins
Dr. Sæmundur Rögnvaldsson presents the results of the first large and prospective examination of MGUS cases with multiple paraproteins.
Abstract title:
Monoclonal Gammopathy of Undetermined Significance…
Videos
Iceland’s iStopMM Study Revises Definition of Free Light Chains in Serum and Light Chain Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Thorir Einarsson Long discusses an aspect of the iStopMM study, a large population-based trial, that focused on light chain monoclonal…
Videos
In this week’s video, Dr. Brian G.M. Durie discusses various possible causes of kidney damage in myeloma patients.
BOTTOM LINE…